Literature DB >> 2547827

21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis.

R Azziz1, H A Zacur.   

Abstract

21-Hydroxylase-deficient late-onset adrenal hyperplasia (LOAH) appears to affect 1-6% of hyperandrogenic women. Screening and diagnostic criteria for LOAH have not been well established, as these patients are clinically indistinguishable from other hyperandrogenic women. The following prospective study was undertaken to 1) determine the predictive value of screening hyperandrogenic women for LOAH with a morning follicular phase basal 17-hydroxyprogesterone (17-HP) level and 2) compare the various in vivo estimates of 21-hydroxylase activity after adrenal stimulation for the diagnosis of LOAH. Twenty-one euandrogenic control women (physically normal, without hirsutism, with regular menses, and a negative family history) were studied. The clinical population consisted of 164 consecutive unselected patients seen at the Division of Reproductive Endocrinology and Infertility of Johns Hopkins University School of Medicine between 1983 and 1987 demonstrating hirsutism and/or hyperandrogenic oligomenorrhea. Controls and patients underwent acute adrenal stimulation with 1 mg ACTH-(1-24), administered in the morning to fasting patients in the follicular phase of their menstrual cycle. Blood was sampled before and 30 min after ACTH-(1-24) administration. Steroid RIA determinations were performed for 17-HP, progesterone, testosterone, dehydroepiandrosterone sulfate, androstenedione, FSH, LH, and PRL. Three estimates of 21-hydroxylase activity were studied: the 17-HP level 30 min post-ACTH (17-HP30), the change in 17-HP (delta 17-HP0-30) and the summed rate of change in 17-HP and progesterone ([delta 17-HP0-30) + delta P0-30]/30 min). The upper 95th percentiles for these estimates of 21-hydroxylase activity in control women were 9.6 nmol/L (316 ng/dL), 8.8 nmol/L (292 ng/dL), and 0.39 nmol/L.min (13 ng/dL.min), respectively. Thirteen of 164 (7.9%) hyperandrogenic women had at least 1 abnormal 21-hydroxylase measurement. Four of these women (2.4%) had 17-HP measurements 3- to 20-fold above the upper normal 95th percentile (17-HP30 greater than 36.3 nmol/L or 1200 ng/dL) and were considered as suffering from LOAH. In our population the 3 measures of 21-hydroxylase studied clearly differentiated the LOAH women from all others, although a single 17-HP level 30 min post-ACTH was the simplest and most cost effective. Nine other hyperandrogenic women (5.5%) had at least 1 abnormal 21-hydroxylase measurement less than 3-fold the upper normal 95th percentile value and were designated as having mild 21-hydroxylase deficiency.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547827     DOI: 10.1210/jcem-69-3-577

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  HLADR5 and C4BQO high frequency and antinuclear antibodies positivity in patients with 21 hydroxylase deficiency from Campania region.

Authors:  F Parlato; G Pisano; G Misiano; E Cosentini; C Cacciapuoti; M R Cavalcanti; M Brai; A Bellastella
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

Review 2.  Non-classic adrenal hyperplasia in hyperandrogenism: a reappraisal.

Authors:  C Morán; E S Knochenhauer; R Azziz
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

3.  Late-onset congenital adrenal hyperplasia in a group of hyperandrogenic women.

Authors:  D K Hassíakos; J P Toner; G S Jones; H W Jones
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

4.  CYP17 gene analysis in hyperandrogenised women with and without exaggerated 17-hydroxyprogesterone response to ovarian stimulation.

Authors:  M Liović; J Prezelj; A Kocijancic; G Majdic; R Komel
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

5.  Girls with virilisation in childhood: a diagnostic protocol for investigation.

Authors:  M E Street; A Weber; C Camacho-Hübner; L A Perry; C E Brain; A M Cotterill; M O Savage
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

Review 6.  21-Hydroxylase deficiency: from molecular genetics to clinical presentation.

Authors:  E Trakakis; D Laggas; E Salamalekis; G Creatsas
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

7.  New reliable biochemical marker for screening 21 alpha-hydroxylase deficiency without index person among hirsute women in agreement with HLA-haplotyping.

Authors:  A Chryssikopoulos; I Phocas; A Sarandakou; E Trakakis; D Rizos
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

8.  Success of glucocorticoid replacement therapy on fertility in two adult males with 21-CAH homozygote classic form.

Authors:  R Valentino; S Savastano; A P Tommaselli; M T Scarpitta; M Dorato; M Gigante; E Calvanese; M Carlino; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

9.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

10.  Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome.

Authors:  Ricardo Azziz; Wendy Y Chang; Frank Z Stanczyk; Keslie Woods
Journal:  Fertil Steril       Date:  2012-10-31       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.